The effectiveness of cardiac contractility modulation in patients with chronic heart failure and atrial fibrillation: results of the 12-month follow-up
- Authors: Safiullina A.A.1, Uskach T.M.1, Sapelnikov O.V.1, Grishin I.R.1, Cherkashin D.I.1, Amanatova V.A.1, Akchurin R.S.1, Tereshchenko S.N.1
-
Affiliations:
- Chazov National Medical Research Center of Cardiology
- Issue: Vol 94, No 9 (2022)
- Pages: 1078-1084
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/112040
- DOI: https://doi.org/10.26442/00403660.2022.09.201840
- ID: 112040
Cite item
Full Text
Abstract
Aim. To evaluate the efficacy, safety and effect on the prognosis of cardiac contractility modulation (CCM) in patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction and atrial fibrillation compared with the group of only optimal drug therapy (ODT) of the 12-month follow-up.
Materials and methods. Patients (n=200) were sequentially included in two groups: group 1 patients with CHF who are on ODT in combination with implanted CCM devices (n=100), group 2 comparison – patients with CHF who receive only ODT (n=100). Initially and after 12 months, 12-channel electrocardiography (ECG), transthoracic echocardiography, daily ECG-monitoring, determination of the level of NT-proBNP, a six-minute walk test and an assessment of the quality of life according to the Minnesota Questionnaire were performed.
Results. In the CCM therapy group, a significant clinical improvement was revealed, which was expressed in the form of a decrease in functional class CHF by NYHA (New York Heart Association), an increase in the distance of a six-minute walk test and an improvement in the quality of life according to Minnesota Questionnaire, as well as an improvement in left ventricle contractile function compared to the ODT group. The absence of a proarrhythmogenic effect of the CCM was shown. There was a significant decrease in the frequency of the readmission due to CHF and the probability of achieving the combined endpoint in the CCM therapy group compared with only ODT.
Conclusion. The use of CCM in patients with CHF and atrial fibrillation is an effective and safe method of therapy that leads to the development of reverse remodeling of the myocardium, improves the clinical status of patients and reduces the frequency of readmission due to decompensation of CHF.
Full Text
##article.viewOnOriginalSite##About the authors
Alfiya A. Safiullina
Chazov National Medical Research Center of Cardiology
Author for correspondence.
Email: a_safiulina@mail.ru
ORCID iD: 0000-0003-3483-4698
канд. мед. наук, науч. сотр. отд. заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowTatiana M. Uskach
Chazov National Medical Research Center of Cardiology
Email: a_safiulina@mail.ru
ORCID iD: 0000-0003-4318-0315
д-р мед. наук, вед. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowOleg V. Sapelnikov
Chazov National Medical Research Center of Cardiology
Email: a_safiulina@mail.ru
ORCID iD: 0000-0002-5186-2474
д-р мед. наук, гл. науч. сотр. лаб. хирургических и рентгенхирургических методов лечения нарушений ритма сердца
Russian Federation, MoscowIgor R. Grishin
Chazov National Medical Research Center of Cardiology
Email: a_safiulina@mail.ru
ORCID iD: 0000-0002-2689-2751
канд. мед. наук, ст. науч. сотр. лаб. хирургических и рентгенхирургических методов лечения нарушений ритма сердца
Russian Federation, MoscowDmitrii I. Cherkashin
Chazov National Medical Research Center of Cardiology
Email: a_safiulina@mail.ru
ORCID iD: 0000-0003-1679-1719
канд. мед. наук, сердечно-сосудис- тый хирург лаб. хирургических и рентгенхирургических методов лечения нарушений ритма сердца
Russian Federation, MoscowValeriia A. Amanatova
Chazov National Medical Research Center of Cardiology
Email: a_safiulina@mail.ru
ORCID iD: 0000-0002-0678-9538
лаборант-исследователь отд. заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowRenat S. Akchurin
Chazov National Medical Research Center of Cardiology
Email: a_safiulina@mail.ru
ORCID iD: 0000-0002-6726-4612
акад. РАН, д-р мед. наук, проф., зам. ген. дир. по хирургии, рук-ль отд. сердечно-сосудистой хирургии
Russian Federation, MoscowSergey N. Tereshchenko
Chazov National Medical Research Center of Cardiology
Email: a_safiulina@mail.ru
ORCID iD: 0000-0001-9234-6129
д-р мед. наук, проф., рук. отд. заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowReferences
- Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure with Reduced Ejection Fraction: A Review. JAMA. 2020;324(5):488-504. doi: 10.1001/jama.2020.10262
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: 10.1093/eurheartj/ehab368
- Glikson M, Nielsen JC, Kronborg NB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-520. doi: 10.1093/eurheartj/ehab364
- Lund LH, Jurga J, Edner M, et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J. 2013;34(7):529-39. doi: 10.1093/eurheartj/ehs305
- Abraham WT, Kuck KH, Goldsmith RL, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018;6(10):874-83. doi: 10.1016/j.jchf.2018.04.010
- Borggrefe MM, Lawo T, Butter C, et al. Randomized, double-blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29(8):1019-28. doi: 10.1093/eurheartj/ehn020
- Kuschyk J, Falk P, Demming T, et al. Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system. Eur J Heart Fail. 2021;23(7):1160-9. doi: 10.1002/ejhf.2202
- Giallauria F, Cuomo G, Parlato A, et al. A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life. ESC Heart Fail. 2020;7(5):2922-32. doi: 10.1002/ehf2.12902
- Campbell CM, Kahwash R, Abraham WT. Optimizer Smart in the treatment of moderate-to-severe chronic heart failure. Future Cardiol. 2020;16(1):13-25. doi: 10.2217/fca-2019-0044
- Kuschyk J, Nägele H, Heinz-Kuck K, et al. Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT). Int J Cardiol. 2019;277:173-7. doi: 10.1016/j.ijcard.2018.10.086
- Терещенко С.Н., Галявич А.С., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311-74 [Tereshchenko SN, Galyavich AS, Uskach TM, et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311-74 (in Russian)]. doi: 10.15829/1560-4071-2020-4083
- Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021;S1071-9164(21)00050-6. doi: 10.1016/j.cardfail.2021.01.022
- Амирасланов А.Ю., Васковский В.А., Артюхина Е.А., Ревишвили А.Ш. Отдаленные результаты хирургического лечения пациентов с хронической сердечной недостаточностью с помощью имплантации кардиомодулирующих устройств. Вестник аритмологии. 2022;29(1):17-23 [Amiraslanov AYu, Vaskovskiy VA, Artyukhina EA, Revishvili AS. Long-term results of cardiac contractility modulation in patients with chronic heart failure. Journal of Arrhythmology. 2022;29(1):17-23 (in Russian)]. doi: 10.35336/VA-2022-1-03
- Grigioni F, Carinci V, Boriani G, et al. Accelerated QRS widening as an independent predictor of cardiac death or of the need for heart transplantation in patients with congestive heart failure. J Heart Lung Transplant. 2002;21(8):899-902. doi: 10.1016/s1053-2498(02)00431-x
- Röger S, Michels J, Heggemann F, et al. Long term impact of cardiac contractility modulation on QRS duration. J Electrocardiol. 2014;47(6):936-40. doi: 10.1016/j.jelectrocard.2014.08.011
- Pappone C, Augello G, Rosanio S, et al. First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multicenter study. J Cardiovasc Electrophysiol. 2004;15(4):418-27. doi: 10.1046/j.1540-8167.2004.03580.x
- Stix G, Borggrefe M, Wolpert C, et al. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J. 2004;25(8):650-5. doi: 10.1016/j.ehj.2004.02.027
Supplementary files
![](/img/style/loading.gif)